Objective
To evaluate the efficacy and safety of an intravenous human monoclonal antibody to cytomegalovirus (CMV), MSL-109, as adjuvant treatment for CMV retinitis.
Methods
Two hundred nine patients with acquired immunodeficiency syndrome and active CMV retinitis were enrolled in a multicenter, phase 2/3, randomized, placebocontrolled clinical trial. Patients received adjuvant treatment with MSL-109, 60 mg intravenously every 2 weeks, or placebo. Randomization was stratified on the basis of whether patients had untreated or relapsed retinitis. Primary drug therapy for CMV retinitis was determined by the treating physician.
Results
The rates of retinitis progression, as evaluated in a masked fashion, were 3.04/person-year in the MSL-109—treated group and 3.05/person-year in the placebo-treated group (P=.98; Wald test); the median times to progression were 67 days in the MSL-109—treated group and 65 days in the placebo-treated group. No differences between the 2 groups were noted in the rates of increase in retinal area involved by CMV, visual field loss, or visual acuity outcomes. The mortality rate in the MSL-109—treated group was 0.68/person-year, and in the placebo-treated group, 0.31/person-year (P=.01). The mortality difference was not explained by differences in baseline variables or in concurrent antiretroviral therapy. Among patients with newly diagnosed retinitis, mortality rates were similar (MSL-109, 0.41/person-year; placebo, 0.42/person-year; P=.95), whereas among patients with relapsed retinitis the MSL-109—treated group had a greater mortality rate (MSL-109, 0.83/person-year; placebo, 0.24/person-year; P=.003). However, the mortality rate in the placebo-treated patients with relapsed CMV retinitis was lower than that in the placebo-treated patients with newly diagnosed CMV retinitis and lower than that in other trials of patients with relapsed CMV retinitis.
Conclusions
Intravenous MSL-109, 60 mg every 2 weeks, appeared to be ineffective adjuvant therapy for CMV retinitis. The mortality rate was higher in the MSL-109—treated group, but the reasons for this difference remain uncertain.
Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease
Stone et al.
J Antimicrob Chemother 2006;57:585-588.
ABSTRACT
| FULL TEXT
Intravitreally Injected Human Immunoglobulin Attenuates the Effects of Staphylococcus aureus Culture Supernatant in a Rabbit Model of Toxin-Mediated Endophthalmitis
Perkins et al.
Arch Ophthalmol 2004;122:1499-1506.
ABSTRACT
| FULL TEXT
Results of a Cytomegalovirus (CMV)-Specific CD8+/Interferon-{gamma}+ Cytokine Flow Cytometry Assay Correlate with Clinical Evidence of Protective Immunity in Patients with AIDS with CMV Retinitis
Jacobson et al.
The Journal of Infectious Disease 2004;189:1362-1373.
ABSTRACT
| FULL TEXT
Risk of Vision Loss in Patients With Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome
Kempen et al.
Arch Ophthalmol 2003;121:466-476.
ABSTRACT
| FULL TEXT
Influence of Filgrastim (Granulocyte Colony-Stimulating Factor) on Human Immunodeficiency Virus Type 1 RNA in Patients with Cytomegalovirus Retinitis
Davidson et al.
The Journal of Infectious Disease 2002;186:1013-1018.
ABSTRACT
| FULL TEXT
Photographic Measures of Cytomegalovirus Retinitis as Surrogates for Visual Outcomes in Treated Patients
Holbrook et al.
Arch Ophthalmol 2001;119:554-563.
ABSTRACT
| FULL TEXT
Risk Factors for Advancement of Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome
Holbrook et al.
Arch Ophthalmol 2000;118:1196-1204.
ABSTRACT
| FULL TEXT
